Omnicell, Inc. (OMCL) Holdings Increased by Pier Capital LLC

Pier Capital LLC raised its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 34.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,926 shares of the company’s stock after buying an additional 38,610 shares during the quarter. Omnicell makes up approximately 1.1% of Pier Capital LLC’s holdings, making the stock its 27th largest holding. Pier Capital LLC owned 0.39% of Omnicell worth $7,916,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. BlackRock Inc. grew its holdings in Omnicell by 0.9% in the 1st quarter. BlackRock Inc. now owns 4,884,888 shares of the company’s stock valued at $212,004,000 after buying an additional 45,697 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of Omnicell by 5.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,833,223 shares of the company’s stock valued at $96,153,000 after purchasing an additional 98,515 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 1.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,538,878 shares of the company’s stock valued at $66,787,000 after purchasing an additional 20,902 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Omnicell by 3.2% in the 1st quarter. Champlain Investment Partners LLC now owns 1,505,445 shares of the company’s stock valued at $65,336,000 after purchasing an additional 46,390 shares in the last quarter. Finally, Westwood Holdings Group Inc. lifted its stake in shares of Omnicell by 23.0% in the 1st quarter. Westwood Holdings Group Inc. now owns 650,078 shares of the company’s stock valued at $28,213,000 after purchasing an additional 121,460 shares in the last quarter. Institutional investors own 98.61% of the company’s stock.

Several equities analysts have recently weighed in on the company. BidaskClub raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 9th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research note on Monday. Piper Jaffray Companies lifted their price objective on Omnicell from $44.00 to $55.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. TheStreet raised Omnicell from a “c+” rating to a “b” rating in a research note on Friday, July 27th. Finally, Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Friday, July 27th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $53.80.

NASDAQ OMCL opened at $63.75 on Thursday. The stock has a market capitalization of $2.51 billion, a PE ratio of 354.17, a PEG ratio of 3.01 and a beta of 0.91. Omnicell, Inc. has a 1-year low of $39.75 and a 1-year high of $65.55. The company has a current ratio of 1.78, a quick ratio of 1.27 and a debt-to-equity ratio of 0.31.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 26th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.07. The business had revenue of $188.70 million for the quarter, compared to analyst estimates of $188.80 million. Omnicell had a return on equity of 5.88% and a net margin of 5.27%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 EPS. sell-side analysts expect that Omnicell, Inc. will post 1.35 EPS for the current fiscal year.

In related news, insider Peter J. Kuipers sold 2,818 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $53.06, for a total transaction of $149,523.08. Following the transaction, the insider now directly owns 54,370 shares of the company’s stock, valued at approximately $2,884,872.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter J. Kuipers sold 9,144 shares of the business’s stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $49.57, for a total value of $453,268.08. Following the transaction, the insider now directly owns 56,970 shares in the company, valued at $2,824,002.90. The disclosure for this sale can be found here. Insiders sold a total of 86,845 shares of company stock worth $4,660,212 over the last ninety days. Corporate insiders own 3.71% of the company’s stock.

Omnicell Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

See Also: Relative Strength Index

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply